Literature DB >> 6144197

Somatostatinoma syndrome accompanied by overproduction of pancreatic polypeptide.

C Nakanome, M Koizumi, H Fujiya, H Akai, T Toyota, Y Goto, J Kameyama, K Miyakawa, K Hanew.   

Abstract

A case of somatostatin and pancreatic polypeptide (PP) producing tumor of the pancreas is presented. A 65-year-old woman was admitted for the evaluation of the tumor in the right upper quadrant of the abdomen. Clinical abnormalities included diabetic glucose intolerance, pancreatic insufficiency and marked dilatation of gallbladder. Marked high concentration of plasma PP and low levels of plasma insulin and glucagon were observed before operation. Plasma insulin concentrations in response to oral glucose tolerance test and arginine infusion were markedly low. A large quantity of somatostatin (4,300 ng/g ww) as well as PP (1,340 ng/g ww) was detected in the tumor, and somatostatin cells and PP cells were determined by immunofluorescence studies. After operation, pancreatic insufficiency and glucose intolerance were improved, and the patient made a favorable progress.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144197     DOI: 10.1620/tjem.142.201

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  3 in total

Review 1.  Elevated pancreatic polypeptide levels in pancreatic neuroendocrine tumors and diabetes mellitus: causation or association?

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Pancreas       Date:  2014-05       Impact factor: 3.327

2.  Cystic endocrine tumor of the pancreas.

Authors:  T Nojima; T Kojima; H Kato; K Inoue; K Nagashima
Journal:  Int J Pancreatol       Date:  1991-09

3.  Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Eleni Papoutsi; Vasiliki Ntella; Prodromos Kanavidis; Athanasios Sioulas; Marina Tsoli; Georgios Charalampopoulos; Michail Vailas; Evangelos Felekouras
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.